32-76% Reduction in cns leukemia with a pharmacokinetically-derived intrathecal methotrexate (IT MTX) dosage regimen and a lower cranial radiation dose

A. Bleyer, P. Coccia, H. Sather

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Fingerprint

Dive into the research topics of '32-76% Reduction in cns leukemia with a pharmacokinetically-derived intrathecal methotrexate (IT MTX) dosage regimen and a lower cranial radiation dose'. Together they form a unique fingerprint.